Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 13/20 | 0.64 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24029785 | 0.91 | SLC5A1 (0.55) | SLC5A1SLC5A2ALDH1A1POLB | |
| SCHEMBL20803461 | 0.89 | SLC5A1 (0.51) | SLC5A1SLC5A2ALDH1A1POLBLMNA | |
| SCHEMBL24029745 | 0.88 | SLC5A1 (0.52) | SLC5A1SLC5A2ALDH1A1POLB | |
| SCHEMBL24030100 | 0.85 | SLC5A1 (0.50) | SLC5A1SLC5A2ALDH1A1POLB | |
| SCHEMBL22320163 | 0.84 | SLC5A1 (0.52) | SLC5A1SLC5A2POLBLMNA | |
| SCHEMBL24030116 | 0.82 | SLC5A1 (0.47) | SLC5A1SLC5A2POLB | |
| SCHEMBL27272305 | 0.81 | SLC5A1 (0.75) | SLC5A1SLC5A2 | |
| SCHEMBL28584968 | 0.80 | SLC5A1 (0.49) | SLC5A1SLC5A2POLBLMNA | |
| SCHEMBL24030004 | 0.80 | SLC5A1 (0.47) | SLC5A1SLC5A2ALDH1A1LMNA | |
| SCHEMBL22876091 | 0.80 | SLC5A1 (0.80) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216411-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2024-07-04 | — | — | US | disclosed |
| EP-3950684-A1 | GLUCOSIDE DERIVATIVE THAT ACTS AS SGLT1 INHIBITOR AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3489226-B1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | LEXICON PHARMACEUTICALS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020200153-A1 | GLUCOSIDE DERIVATIVE THAT ACTS AS SGLT1 INHIBITOR AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216411-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | SLC5A1, CFTR, SLC5A2 | SLC5A1 1/4885SLC5A2 3/4885ALDH1A1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.